Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
Cancer Immunology, Immunotherapy · 07.11.2024 · 74 (1)
DOI: 10.1007/s00262-024-03869-1 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 07.11.2024. Verfasst von Cecilia Olsson Ladjevardi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Neoplasms, Immune Checkpoint Inhibitors, B7-H1 Antigen. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancerföreningen i Stockholm, Akademiska Sjukhuset, Foundation Stiftelsen Onkologiska Klinikens i Uppsala Forskningsfond.
Abstract (Originalsprache)
Immunotherapy with PD-1 or PD-L1 inhibitors has become an essential treatment strategy for a growing number of malignancies. These treatments have a risk for immune-related adverse events (IRAEs). Pooled analyses based on clinical trials show a favorable toxicity profile for treatment with PD-L1 compared to PD-1 inhibitors. This study aimed to investigate differences in IRAEs between patients with advanced solid malignances treated with PD-L1 and PD-1 inhibitors in a real-world setting. We conducted a retrospective cohort study at four Swedish Regions. Patients (n = 605) treated for advanced cancer with a PD-L1 or PD-1 inhibitor in monotherapy between June 2016 and August 2022 were included. Non-small cell lung cancer (NSCLC) was the most common malignant disease (n = 251; 41.5%), followed by malignant melanoma (n = 173; 28.6%), renal cell carcinoma (n = 71; 11.7%) and urothelial carcinoma (n = 35; 5.8%). Among patients receiving PD-L1 inhibitors, NSCLC (94.4%) was the predominant malignancy, whereas for those treated with PD-1 inhibitor, malignant melanoma constituted the most prevalent malignancy (34.5%). Discontinuation of treatment due to IRAEs overall and IRAEs grade ≥ 2 were significantly less common in patients treated with PD-L1 compared to PD-1 inhibitors [Odds Ratio (OR): 0.38 (95% Confidence Interval (CI) 0.16–0.88) and OR: 0.63 (95% CI 0.35–0.98) respectively]. Any grade IRAE, IRAE grade ≥ 3 and multiple IRAEs were numerically more frequent in patients treated with PD-1 inhibitors.In conclusion, our study of patients with advanced solid malignancies in a real-world setting supports the results from clinical trials demonstrating a favorable toxicity profile for PD-L1 inhibitors versus PD-1 inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Genetics, and Pathology, Uppsala University, Uppsala, Sweden.
- Department of Oncology, Uppsala University Hospital, 751 85, Uppsala, Sweden.
- Thoracic Oncology Center, Theme Cancer, Karolinska University Hospital, 171 76, Stockholm, Sweden.
- Department of Oncology-Pathology, Karolinska Institutet, 171 77, Stockholm, Sweden.
- Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
- Department of Oncology, Mälarsjukhuset, 633 49, Eskilstuna, Sweden.
Förderung
- Cancerföreningen i Stockholm
- Akademiska Sjukhuset
- Foundation Stiftelsen Onkologiska Klinikens i Uppsala Forskningsfond
- Örebro University
Zitieren
APA
Ladjevardi, C. O., Skribek, M., Koliadi, A., Rydén, V., El-Naggar, A. I., Digkas, E., Valachis, A., & Ullenhag, G. J. (2024). Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer. Cancer Immunology, Immunotherapy, 74(1). https://doi.org/10.1007/s00262-024-03869-1
Vancouver
Ladjevardi CO, Skribek M, Koliadi A, Rydén V, El-Naggar AI, Digkas E, et al. Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer. Cancer Immunology, Immunotherapy. 2024;74(1). doi:10.1007/s00262-024-03869-1
BibTeX
@article{Ladjevardi2024,
author = {Ladjevardi, Cecilia Olsson and Skribek, Marcus and Koliadi, Anthoula and Rydén, Viktoria and El-Naggar, Ali Inan and Digkas, Evangelos and Valachis, Antonios and Ullenhag, Gustav J},
title = {Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
volume = {74},
number = {1},
doi = {10.1007/s00262-024-03869-1}
}
EUVIMED